Ottobock SE & Co. KGaA

Ottobock SE & Co. KGaA makes prosthetic and orthotic components, including microprocessor knees, and runs a network of its own patient care clinics. Prosthetist Otto Bock founded the company in Berlin in 1919; it is headquartered in Duderstadt, Germany, with its North American base in Austin, Texas. The company also markets SuitX industrial exoskeletons. It reports in two product categories, Products & Components (B2B) and Patient Care (B2C), across EMEA, Americas and APAC.

Scale

At the IPO the company reported nearly 9,300 full-time equivalent employees, around 400 patient care clinics and activity in 45 countries. For fiscal 2025 it reported core revenue of EUR 1.6 billion, up 11.7 percent (10.6 percent organic), and underlying core EBITDA of EUR 415.3 million, a 26.0 percent margin. Oliver Jakobi is CEO and Dr. Arne Kreitz is CFO.

IPO and ownership

Ottobock priced its IPO at EUR 66.00 per share on October 7, 2025, the top of a EUR 62 to 66 range, and began trading on the Prime Standard of the Frankfurt Stock Exchange on October 9, 2025 (ISIN DE000BCK2223, ticker OBCK). The placement covered 12,236,173 shares, including 1,515,151 new shares, for gross proceeds of EUR 807.6 million; about EUR 100 million went to the company and the rest to selling shareholder Näder Upside Vermögensverwaltungs GmbH. Market capitalization was about EUR 4.2 billion with a 19.12 percent free float. The Näder family keeps more than 80 percent.

2026 moves

The company appointed Dr. Katarzyna Mazur-Hofsaess to its Management Board (June 24, 2026), announced a neuro-orthotics acquisition (July 7, 2026) and reported higher first-half revenue and margin (August 13, 2026). Its 2026 outlook calls for 5.0 to 8.0 percent organic core growth.